Screening in Oculopharyngeal Muscular Dystrophy

Sponsor
University of Florida (Other)
Overall Status
Completed
CT.gov ID
NCT02877784
Collaborator
(none)
8
1
10
0.8

Study Details

Study Description

Brief Summary

Oculopharyngeal muscular dystrophy (OPMD) is a rare myopathic disease that results in progressive degeneration of the oral and pharyngeal muscular, resulting in severe dysphagia and dysarthria. OPMD is considered a rare disease; therefore, limited research is available on the natural progression of the disease or the utility of biomarkers to identify swallowing impairment. The aim of this study is:

  1. To identify accurate, reliable and non-invasive clinical markers of swallowing impairment

  2. To determine the discriminate ability of these markers to identify impairments in swallow safety and swallowing efficiency.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Videofluoroscopic swallowing study
  • Other: Functional Oral Intake Scale
  • Other: Eating Assessment Tool-10

Detailed Description

Participants will be recruited from the Neurology clinic at the University of Florida. The single evaluation will occur in the PIs research laboratory at the University of Florida, Gainesville, Florida.

Study Design

Study Type:
Observational
Actual Enrollment :
8 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Determination of Accurate Screening Tools for Dysphagia in Oculopharyngeal Muscular Dystrophy
Study Start Date :
Oct 1, 2016
Actual Primary Completion Date :
Aug 1, 2017
Actual Study Completion Date :
Aug 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Screening

Participants enrolled will undergo testing of the swallowing mechanism

Procedure: Videofluoroscopic swallowing study
Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
Other Names:
  • VFSS
  • modified barium swallow (MBS)
  • Other: Functional Oral Intake Scale
    The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
    Other Names:
  • FOIS
  • Other: Eating Assessment Tool-10
    The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
    Other Names:
  • EAT-10
  • Outcome Measures

    Primary Outcome Measures

    1. Dynamic Imaging Grade of Swallowing Toxicity [Baseline]

      Global Metric of swallowing Safety and Efficiency

    Secondary Outcome Measures

    1. Dietary intake as confirmed by Functional Oral Intake Scale (FOIS) [Baseline]

      FOIS is a validated 7-point scale indexing an individual's ability to intake food on a day-to-day basis. TUBE DEPENDENT (levels 1-3) No oral intake Tube dependent with minimal/inconsistent oral intake Tube supplements with consistent oral intake TOTAL ORAL INTAKE (levels 4-7) Total oral intake of a single consistency Total oral intake of multiple consistencies requiring special preparation Total oral intake with no special preparation, but must avoid specific foods or liquid items Total oral intake with no restrictions

    2. Participant perception of swallowing related symptoms as confirmed by The Eating Assessment Tool 10 (EAT-10) [Baseline]

      EAT-10 is a 10-item validated self-administered dysphagia severity symptom survey. Score is 0 - 40 with 0 being the best possible score and 40 the worst possible score.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • diagnosis of oculopharyngeal muscular dystrophy

    • no allergies to barium or capsaicin,

    • no tracheotomy or mechanical ventilation

    • no significant concurrent respiratory disease (e.g., COPD).

    Exclusion Criteria:
    • Pregnant Women

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Florida Gainesville Florida United States 32610

    Sponsors and Collaborators

    • University of Florida

    Investigators

    • Principal Investigator: Emily Plowman, PhD, University of Florida

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Florida
    ClinicalTrials.gov Identifier:
    NCT02877784
    Other Study ID Numbers:
    • IRB201601374
    First Posted:
    Aug 24, 2016
    Last Update Posted:
    Mar 27, 2020
    Last Verified:
    Mar 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of Florida
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 27, 2020